FunPep (4881) Stock Overview
Engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4881 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
FunPep Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥79.00 |
| 52 Week High | JP¥130.00 |
| 52 Week Low | JP¥75.00 |
| Beta | 0.95 |
| 1 Month Change | -22.55% |
| 3 Month Change | -3.66% |
| 1 Year Change | -21.00% |
| 3 Year Change | -60.70% |
| 5 Year Change | -83.47% |
| Change since IPO | -89.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4881 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -1.3% | 2.2% | 2.9% |
| 1Y | -21.0% | 12.5% | 49.6% |
Return vs Industry: 4881 underperformed the JP Biotechs industry which returned 12.5% over the past year.
Return vs Market: 4881 underperformed the JP Market which returned 49.6% over the past year.
Price Volatility
| 4881 volatility | |
|---|---|
| 4881 Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4881's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4881's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 15 | Toshimi Miyoshi | www.funpep.co.jp |
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis. It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes.
FunPep Company Limited Fundamentals Summary
| 4881 fundamental statistics | |
|---|---|
| Market cap | JP¥3.23b |
| Earnings (TTM) | -JP¥1.91b |
| Revenue (TTM) | n/a |
Is 4881 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4881 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.91b |
| Earnings | -JP¥1.91b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -46.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4881 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 00:15 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FunPep Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.